Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Newron Pharmaceuticals SpA's EV-to-OCF or its related term are showing as below:
XSWX:NWRN'
s EV-to-OCF Range Over the Past 10 Years
Min: -31.9 Med: -6.49 Max: 20.39
Current: 8.8
During the past 13 years, the highest EV-to-OCF of Newron Pharmaceuticals SpA was 20.39. The lowest was -31.90. And the median was -6.49.
XSWX:NWRN's EV-to-OCF is ranked worse than 82.09% of 1407
companies
in the Biotechnology industry
Industry Median: -3.61
vs XSWX:NWRN: 8.80
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Newron Pharmaceuticals SpA's PE Ratio (TTM) for today is calculated as:
Newron Pharmaceuticals SpA's share price for today is CHF12.58.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.616.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Newron Pharmaceuticals SpA EV-to-OCF Related Terms
Newron Pharmaceuticals SpA EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:NWRN vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's EV-to-OCF falls into.
Newron Pharmaceuticals SpA's current Enterprise Value is CHF270.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF30.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA (XSWX:NWRN) has a EV-to-OCF of 8.91 as of Aug. 21, 2026. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #1155 out of 1407 companies in the Biotechnology industry, placing it in the top 82.1%.
Is Newron Pharmaceuticals SpA's EV-to-OCF too high?
Newron Pharmaceuticals SpA's current EV-to-OCF is 8.91. Based on the distribution chart, Newron Pharmaceuticals SpA ranks #1155 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #1155 out of 1407 companies for EV-to-OCF. This places Newron Pharmaceuticals SpA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Newron Pharmaceuticals SpA's current EV-to-OCF is 8.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF13.28, compared to a current price of CHF12.58 — trading 5.3% below its estimated fair value. The current EV-to-OCF is 8.91. Newron Pharmaceuticals SpA's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current EV-to-OCF is 8.91 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued.
The current stock price of CHF12.58 is trading 5.3% below its estimated GF Value™ of CHF13.28.
GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.
Key valuation signals for XSWX:NWRN:
EV-to-OCF: 8.91
GF Value™: CHF13.28 vs. price of CHF12.58 (5.3% below fair value)
No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
76GF Score
Get the complete analysis for XSWX:NWRN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NWRN has been successfully added to your 
